Vyndamax

Oman · access guide

How to access Vyndamax from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Oman patient diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), wild-type or hereditary, may receive a prescription for Vyndamax (tafamidis 61 mg, once daily) from their treating cardiologist or heart-failure specialist. Vyndamax is FDA-approved for ATTR-CM to reduce cardiovascular mortality and cardiovascular-related hospitalisation, and it is the established standard-of-care TTR stabiliser in the class. It is manufactured by Pfizer. Stocking through Oman domestic supply chain for this specific indication and strength is inconsistent, which is why access typically runs through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient pathway.

This guide explains the legal pathway, the documentation your cardiologist prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Vyndamax is an oral transthyretin (TTR) stabiliser taken once daily as a single 61 mg soft-gel capsule, the convenience successor to the four-capsule 80 mg Vyndaqel regimen, with equivalent clinical effect. By binding circulating TTR tetramers, it slows the dissociation step that precedes amyloid fibril deposition in the myocardium. Eligibility is anchored to a confirmed ATTR-CM diagnosis, typically scintigraphy (PYP / DPD bone-tracer imaging) with or without endomyocardial biopsy, plus exclusion of AL amyloidosis and, where indicated, genetic testing to distinguish hereditary from wild-type disease. Your cardiologist will establish baseline NYHA class, NT-proBNP, troponin, eGFR, and a long-term follow-up cadence. Vyndamax is oral, well-tolerated, and does not require infusion infrastructure, the operational bottleneck is supply continuity, not administration.

Is Vyndamax legally importable into Oman?

Yes, through the DGPADC named-patient import framework. The DGPADC named-patient route allows a Oman-licensed physician to request import of a medicine not locally registered when (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative suits the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the dispensing pharmacy. ATTR-CM has a limited, highly specific set of disease-modifying options, which supports clinical rationale.

How the pathway works, step by step

1. **Consultation with your treating cardiologist.** Documentation of ATTR-CM diagnosis, scintigraphy evidence, AL-exclusion workup, and a clinical rationale letter.
2. **Baseline assessment.** NYHA class, NT-proBNP, troponin, eGFR, and a genetic test result if hereditary ATTR is suspected.
3. **DGPADC named-patient application.** The physician or hospital pharmacy files clinical rationale, patient reference, dosing plan (61 mg once daily), and chain-of-custody commitment.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Vyndamax from authorised distribution under DSCSA.
5. **Ambient shipment.** Vyndamax capsules ship under controlled ambient conditions with chain-of-custody documentation.
6. **Arrival and dispensing.** The hospital pharmacy releases the bottle to the patient with the cardiologist-guided monitoring and refill schedule.

What documentation your physician needs

- Clinical rationale letter confirming ATTR-CM diagnosis and Vyndamax as the indicated therapy
- Verification of Oman medical licence (SCFHS / MOH)
- Copy of PYP / DPD scintigraphy report; endomyocardial biopsy where available
- AL-exclusion workup (serum/urine immunofixation, free light chains)
- Baseline NYHA, NT-proBNP, eGFR
- Hereditary-ATTR genetic report if relevant
- Planned dosing schedule (61 mg daily oral) and annual follow-up plan

Reserve Meds provides a physician documentation kit bundling the templates DGPADC reviewers expect for cardiology named-patient imports.

Costs and timing

Vyndamax for ATTR-CM is a long-duration, chronic therapy, and the annual cost is substantial. Reference US cash-pay for an annual course typically sits in the mid-to-high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote, covering product, shipping, DGPADC documentation handling, customs clearance, and concierge coordination, at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete DGPADC application is submitted. Refills ship on a rolling monthly or quarterly schedule based on your cardiologist's preference.

Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

A culturally-aware note: Ramadan and Hajj seasons can affect refill timing for chronic therapies across the Kingdom. Our concierge coordinates refill cadence with your family's calendar and your hospital pharmacy.

Reserve Meds's role

- **Sourcing.** Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and DGPADC review.
- **Logistics.** Ambient-controlled shipment with chain-of-custody to your prescribing hospital pharmacy.
- **Concierge case lead.** A named point of contact coordinating long-term refills.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.

Frequently asked

Is this legal in Oman? Yes, when executed through the DGPADC named-patient framework with appropriate documentation. See our trust and compliance page.

How is Vyndamax different from Vyndaqel? They are the same active ingredient, tafamidis, in different formulations. Vyndamax is 61 mg tafamidis free acid, taken as a single capsule once daily. Vyndaqel 80 mg is tafamidis meglumine, taken as four 20 mg capsules once daily. The clinical effect is the same; Vyndamax is the simpler regimen.

How does Vyndamax compare with Attruby (acoramidis)? Both are oral TTR stabilisers for ATTR-CM. Vyndamax is the long-established standard-of-care with extensive real-world follow-up. Attruby is a newer (2024-approved) entrant with a distinct binding profile and head-to-head clinical data still accumulating. Your cardiologist will select based on clinical picture and product availability.

Does Vyndamax treat the polyneuropathy form of ATTR? The related Vyndaqel 20 mg strength is labeled for polyneuropathy in some jurisdictions. For hATTR polyneuropathy, TTR-silencer therapies (Amvuttra, Onpattro, Wainua) are commonly used, your neurologist and cardiologist team will select the appropriate agent. We cover these pairs in adjacent guides.

Will private insurance cover this? Cash-pay is the default. Some Oman private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com